EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)ÄquivalenzstudieOpen Access · CC BY-NC-ND 4.0

primary analysis of the RANDOMIZED eortc-2139/columbus-ad trial: Adjuvant encorafenib and binimetinib versus placebo in high-risk stage II BRAF-V600E/K melanoma

Alexander Cj van Akkooi, Michal Kicinski, Anne-Sophie Govaerts, Axel Hauschild, Piotr Rutkowski, Petr Arenberger, Paolo A Ascierto, Piotr Tomczak, Gaëlle Quereux, Federica De Galitiis, Caroline Dutriaux, Christoffer Gebhardt und 26 weitere

European Journal of Cancer · 2026-09 · 245 · 116951

DOI: 10.1016/j.ejca.2026.116951 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2026-09. Verfasst von Alexander Cj van Akkooi und 37 weiteren Autor:innen. Beteiligte Einrichtung: Melanoma Institute Australia, Faculty of Medicine and Health, University of Sydney, and Department of Melanoma and Surgical Oncology, Royal Prince Al…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Benzimidazoles, Carbamates, Melanoma. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Institut de recherche Pierre Fabre, Les Laboratories Pierre Fabre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBenzimidazolesCarbamatesMelanomaProto-Oncogene Proteins B-rafSkin NeoplasmsSulfonamidesAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedChemotherapy, AdjuvantCutaneous Malignant MelanomaDouble-Blind MethodMutationNeoplasm Staging

Stichwörter der Autor:innen

AdjuvantBRAFBinimetinibEncorafenibMEKMelanomaStage II Melanoma

Substanzen

BenzimidazolesbinimetinibBRAF protein, humanCarbamatesencorafenibProto-Oncogene Proteins B-rafSulfonamides

Autor:innen und Institutionen

  • Melanoma Institute Australia, Faculty of Medicine and Health, University of Sydney, and Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Sydney, Australia. Electronic address: alexander.vanakk…
  • EORTC Headquarters, Brussels, Belgium.
  • Department of Dermatology, University Hospital (UKSH), Kiel, Germany.
  • Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Fakultni Nemocnice Kralovske Vinohrady, Prague, Czech Republic.
  • Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy.

Förderung

  • Institut de recherche Pierre Fabre
  • Les Laboratories Pierre Fabre

Zitieren

APA

van Akkooi, A. C., Kicinski, M., Govaerts, A. S., Hauschild, A., Rutkowski, P., Arenberger, P., Ascierto, P. A., Tomczak, P., Quereux, G., De Galitiis, F., Dutriaux, C., Gebhardt, C., Kapiteijn, E., Machet, L., Berciano, M. G., Del Vecchio, M., Jalving, M., Jouary, T., Krajsova, I., …, & Mandala, M. (2026). primary analysis of the RANDOMIZED eortc-2139/columbus-ad trial: Adjuvant encorafenib and binimetinib versus placebo in high-risk stage II BRAF-V600E/K melanoma. European Journal of Cancer, 245, 116951. https://doi.org/10.1016/j.ejca.2026.116951

Vancouver

van Akkooi AC, Kicinski M, Govaerts AS, Hauschild A, Rutkowski P, Arenberger P, et al. primary analysis of the RANDOMIZED eortc-2139/columbus-ad trial: Adjuvant encorafenib and binimetinib versus placebo in high-risk stage II BRAF-V600E/K melanoma. European Journal of Cancer. 2026;245:116951. doi:10.1016/j.ejca.2026.116951

BibTeX
@article{vanAkkooi2026,
  author = {van Akkooi, Alexander Cj and Kicinski, Michal and Govaerts, Anne-Sophie and Hauschild, Axel and Rutkowski, Piotr and Arenberger, Petr and Ascierto, Paolo A and Tomczak, Piotr and Quereux, Gaëlle and De Galitiis, Federica and Dutriaux, Caroline and Gebhardt, Christoffer and Kapiteijn, Ellen and Machet, Laurent and Berciano, Miguel Ga and Del Vecchio, Michele and Jalving, Mathilde and Jouary, Thomas and Krajsova, Ivana and Matkovic, Suzana and Merelli, Barbara and Mortier, Laurent and Pagès-Laurent, Pages-LaurentCecile and Palmieri, Giuseppe and Pracht, Marc and Vantuchova, Yvetta and Massi, Daniela and Elaut, Nathalie and de Schaetzen, Gaetan and Nuyens, Sarah and Jha, Nitish and Klauck, Isabelle and Sansas, Benoît and Vedovato, Jean Claude and Lorigan, Paul C and Long, Georgina V and Eggermont, Alexander Mm and Mandala, Mario},
  title = {primary analysis of the RANDOMIZED eortc-2139/columbus-ad trial: Adjuvant encorafenib and binimetinib versus placebo in high-risk stage II BRAF-V600E/K melanoma},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {245},
  pages = {116951},
  doi = {10.1016/j.ejca.2026.116951}
}
Kostenlos starten →